BIOAGE LABS INC (BIOA) Fundamental Analysis & Valuation

NASDAQ:BIOA • US09077V1008

Current stock price

16.19 USD
-1.6 (-8.99%)
At close:
16.3 USD
+0.11 (+0.68%)
After Hours:

This BIOA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BIOA Profitability Analysis

1.1 Basic Checks

  • In the past year BIOA has reported negative net income.
  • BIOA had a negative operating cash flow in the past year.
BIOA Yearly Net Income VS EBIT VS OCF VS FCFBIOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • BIOA has a Return On Assets (-24.84%) which is comparable to the rest of the industry.
  • The Return On Equity of BIOA (-27.32%) is better than 64.06% of its industry peers.
Industry RankSector Rank
ROA -24.84%
ROE -27.32%
ROIC N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOA Yearly ROA, ROE, ROICBIOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BIOA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOA Yearly Profit, Operating, Gross MarginsBIOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BIOA Health Analysis

2.1 Basic Checks

  • BIOA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BIOA Yearly Shares OutstandingBIOA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
BIOA Yearly Total Debt VS Total AssetsBIOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 14.82 indicates that BIOA is not in any danger for bankruptcy at the moment.
  • BIOA has a better Altman-Z score (14.82) than 88.02% of its industry peers.
  • BIOA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.82
ROIC/WACCN/A
WACCN/A
BIOA Yearly LT Debt VS Equity VS FCFBIOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • BIOA has a Current Ratio of 11.87. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.
  • BIOA has a Current ratio of 11.87. This is amongst the best in the industry. BIOA outperforms 83.33% of its industry peers.
  • A Quick Ratio of 11.87 indicates that BIOA has no problem at all paying its short term obligations.
  • The Quick ratio of BIOA (11.87) is better than 83.85% of its industry peers.
Industry RankSector Rank
Current Ratio 11.87
Quick Ratio 11.87
BIOA Yearly Current Assets VS Current LiabilitesBIOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. BIOA Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BIOA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -17.96% yearly.
  • BIOA is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -28.23% yearly.
EPS Next Y-23.17%
EPS Next 2Y-10.74%
EPS Next 3YN/A
EPS Next 5Y-17.96%
Revenue Next Year1073.07%
Revenue Next 2Y-44.33%
Revenue Next 3Y-34.44%
Revenue Next 5Y-28.23%

3.3 Evolution

BIOA Yearly Revenue VS EstimatesBIOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
BIOA Yearly EPS VS EstimatesBIOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2029 2030 2031 2032 2033 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. BIOA Valuation Analysis

4.1 Price/Earnings Ratio

  • BIOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOA Price Earnings VS Forward Price EarningsBIOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOA Per share dataBIOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as BIOA's earnings are expected to decrease with -10.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.74%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIOA Dividend Analysis

5.1 Amount

  • BIOA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOA Fundamentals: All Metrics, Ratios and Statistics

BIOAGE LABS INC

NASDAQ:BIOA (4/10/2026, 8:07:57 PM)

After market: 16.3 +0.11 (+0.68%)

16.19

-1.6 (-8.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-24
Earnings (Next)05-04
Inst Owners63.04%
Inst Owner Change0%
Ins Owners2.59%
Ins Owner Change-10.81%
Market Cap675.93M
Revenue(TTM)N/A
Net Income(TTM)-75.79M
Analysts83.08
Price Target44.27 (173.44%)
Short Float %3.39%
Short Ratio2.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.16%
Min EPS beat(2)-22.35%
Max EPS beat(2)6.02%
EPS beat(4)3
Avg EPS beat(4)6%
Min EPS beat(4)-22.35%
Max EPS beat(4)33.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)201.02%
Min Revenue beat(2)94.32%
Max Revenue beat(2)307.71%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)44.67%
PT rev (3m)261.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.37%
EPS NY rev (1m)0%
EPS NY rev (3m)1.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 114.24
P/FCF N/A
P/OCF N/A
P/B 2.44
P/tB 2.44
EV/EBITDA N/A
EPS(TTM)-2.24
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-1.42
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS0.14
BVpS6.65
TBVpS6.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.84%
ROE -27.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 331.41%
Cap/Sales 10.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.87
Quick Ratio 11.87
Altman-Z 14.82
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.45%
EPS Next Y-23.17%
EPS Next 2Y-10.74%
EPS Next 3YN/A
EPS Next 5Y-17.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1073.07%
Revenue Next 2Y-44.33%
Revenue Next 3Y-34.44%
Revenue Next 5Y-28.23%
EBIT growth 1Y-61.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.69%
EBIT Next 3Y-10.64%
EBIT Next 5YN/A
FCF growth 1Y-38.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.9%
OCF growth 3YN/A
OCF growth 5YN/A

BIOAGE LABS INC / BIOA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIOAGE LABS INC (BIOA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIOA.


What is the valuation status of BIOAGE LABS INC (BIOA) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOAGE LABS INC (BIOA). This can be considered as Overvalued.


What is the profitability of BIOA stock?

BIOAGE LABS INC (BIOA) has a profitability rating of 1 / 10.